Clinical Trial Update: A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease [Phase 3]

View source ↗

Summary

A Phase 3, placebo-controlled trial evaluating the safety and efficacy of Myozyme (alglucosidase alfa) in late-onset Pompe disease has completed and results hav…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pompe Disease

Drugs mentioned

• Myozyme (alglucosidase alfa)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Pompe Disease (Late-onset), Glycogen Storage Disease Type II (GSD-II) | Phase 3 | Status: COMPLETED | Results posted: 2010-07-23